Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis

Ciudad Universitaria, Spain228 enrolled

Overview

The purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.

The duration of the treatment with alendronate is not well established. The investigators recruited 228 women with postmenopausal osteoporosis. They all received alendronate during the first 3 years of monitoring and were later on randomized to whether different regimens of intermittent treatment or to carry on 3 years more.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

228

Conditions

Osteoporosis

Interventions

alendronateDRUG

several duration of treatment

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * postmenopausal osteoporosis under densitometric criteria of the World Health Organization Exclusion Criteria: * secondary osteoporosis * alteration in analytic parameters (total proteins, calcium, phosphorus, vitamin D, parathyroid hormone, thyroid hormone, transaminase, creatinine)

Locations (1)

University San Carlos Hospital

Madrid, Madrid, Spain

Outcomes

Primary Outcomes

Bone mineral density

Time frame: Every year

Secondary Outcomes

Fractures

Time frame: Every year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.